All News

Otsuka seeks FDA approval for centanafadine, a novel ADHD treatment showing significant efficacy and safety in pivotal trials for all age groups.

Novartis's Itvisma gains FDA approval as the first intrathecal gene therapy for spinal muscular atrophy, promising improved motor function and independence.

Primary care is the ideal setting for management of atopic dermatitis, but certain scenarios, both physical and psychological, call for expert referral.

J&J halts phase 2b AuTonomy trial after anti-tau antibody posdinemab fails to slow clinical decline, marking another setback for tau-targeting therapeutics.

The H3N2 subclade K is dominating early flu season gobally; despite vaccine mismatch, vaccination remains the primary defense against severe illness and hospitalization.

Two new Cochrane reviews confirm HPV vaccines significantly reduce cervical cancer risk, especially when given before age 16, with no serious safety concerns.

Evoke trials testing semaglutide for Alzheimer disease missed primary endpoint, failing to demonstrate benefit on cognition despite positive effects on disease markers.

Topline data show the factor XIa inhibitor cut ischemic stroke risk without increasing ISTH major bleeding, pointing to a possible new option for secondary prevention.

A recent meta-analysis reveals that two-thirds of pregnancies experience unhealthy weight gain, highlighting risks for mothers and babies.

Dorr says symptoms can begin 10 years before cylces cease and explains why the hormonal feast and famine of perimenopause can go unrecognized.

Lisa Larkin, MD, discusses how social media is driving menopause awareness and why primary care physicians must educate themselves to meet patient demand.

The CDC website now claims "studies supporting a link [between vaccines and autism] have been ignored by health authorities."

New research reveals that caffeinated coffee significantly reduces the recurrence of atrial fibrillation, challenging long-held medical advice.

Universal age-based screening, starting at age 40, could detect more than 90% of tumors compared to risk-based screening, according to Feinberg School of Medicine researchers.

Controlling atopic dermatitis signs and symptoms early can alter social, emotional, and functional outcomes, sometimes dramatically.

Emotional red flags in AD, eg, sleep loss, isolation, hopelessness, often go unseen. Quick screening questions can surface the real burden individuals carry.

Growing up with AD carries lifelong emotional consequences. Clinicians who recognize these developmental risks can better support patients at every stage.

Up to 1 in 4 patients with atopic dermatitis face anxiety or depression. Primary care clinicians are key to identifying risk and supporting mental well-being.